Tags: Drug.

Linagliptin (BI-1356 trade names Tradjenta and Trajenta) is a DPP-4 inhibitor developed by Boehringer Ingelheim for treatment of type II diabetes.Linagliptin (once-daily) was approved by the U.S. Food and Drug Administration (FDA) on 2 May 2011 for treatment of type II diabetes. It is being marketed by Boehringer Ingelheim and Lilly.

Linagliptin.png
ATC prefix
A10
ATC suffix
BH05
CAS number
668270-12-0
FDA UNII code
3X29ZEJ4R2
IUPAC name
8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3- methyl-1-[(4-methylquinazolin-2-yl)methyl]-37-dihydro-1H-purine-26-dione
PubChem
10096344

Loading...

This page contains content from the copyrighted Wikipedia article "Linagliptin"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.